Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $181.20 million. The enterprise value is $230.89 million.
| Market Cap | 181.20M |
| Enterprise Value | 230.89M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 114.69 million shares outstanding. The number of shares has increased by 24.95% in one year.
| Shares Outstanding | 114.69M |
| Shares Change (YoY) | +24.95% |
| Shares Change (QoQ) | +5.12% |
| Owned by Insiders (%) | 62.91% |
| Owned by Institutions (%) | 19.66% |
| Float | 51.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.30 |
| Forward PS | 2.51 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.91
| Current Ratio | 0.91 |
| Quick Ratio | 0.68 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.86 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -53.70% |
| Return on Capital (ROIC) | -64.65% |
| Revenue Per Employee | $252,760 |
| Profits Per Employee | -$216,857 |
| Employee Count | 217 |
| Asset Turnover | 0.63 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.58% in the last 52 weeks. The beta is 1.19, so Biodesix's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | +30.58% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 55.77 |
| Average Volume (20 Days) | 299,062 |
Short Selling Information
The latest short interest is 230,715, so 0.20% of the outstanding shares have been sold short.
| Short Interest | 230,715 |
| Short Previous Month | 226,682 |
| Short % of Shares Out | 0.20% |
| Short % of Float | 0.45% |
| Short Ratio (days to cover) | 1.96 |
Income Statement
In the last 12 months, Biodesix had revenue of $54.85 million and -$47.06 million in losses. Loss per share was -$0.54.
| Revenue | 54.85M |
| Gross Profit | 41.83M |
| Operating Income | -35.99M |
| Pretax Income | -47.06M |
| Net Income | -47.06M |
| EBITDA | -32.10M |
| EBIT | -37.38M |
| Loss Per Share | -$0.54 |
Balance Sheet
The company has $11.49 million in cash and $61.18 million in debt, giving a net cash position of -$49.68 million or -$0.43 per share.
| Cash & Cash Equivalents | 11.49M |
| Total Debt | 61.18M |
| Net Cash | -49.68M |
| Net Cash Per Share | -$0.43 |
| Equity (Book Value) | -5.50M |
| Book Value Per Share | -0.05 |
| Working Capital | -2.75M |
Cash Flow
In the last 12 months, operating cash flow was -$30.50 million and capital expenditures -$15.63 million, giving a free cash flow of -$46.12 million.
| Operating Cash Flow | -30.50M |
| Capital Expenditures | -15.63M |
| Free Cash Flow | -46.12M |
| FCF Per Share | -$0.48 |
Margins
Gross margin is 76.27%, with operating and profit margins of -65.62% and -85.80%.
| Gross Margin | 76.27% |
| Operating Margin | -65.62% |
| Pretax Margin | -85.80% |
| Profit Margin | -85.80% |
| EBITDA Margin | -58.52% |
| EBIT Margin | -68.16% |
| FCF Margin | -84.09% |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.95% |
| Shareholder Yield | -24.95% |
| Earnings Yield | -25.97% |
| FCF Yield | -25.45% |
Analyst Forecast
The average price target for Biodesix is $3.15, which is 99.37% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.15 |
| Price Target Difference | 99.37% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biodesix has an Altman Z-Score of -6.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.61 |
| Piotroski F-Score | 3 |